Preventing atherosclerotic events with aspirin, BMJ. 12 janv, vol.324, issue.7329, pp.103-108, 2002. ,
AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions, Eur Heart J. août, vol.28, issue.16, pp.1925-1932, 2007. ,
Randomised trial of prophylactic daily aspirin in British male doctors, Br Med J Clin Res Ed. 30 janv, vol.296, issue.6618, pp.313-319, 1988. ,
, Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework, Lancet Lond Engl. 24 janv, vol.20, issue.3, pp.233-274, 1989.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group, Lancet Lond Engl. 13 juin, vol.351, issue.9118, pp.1755-62, 1998. ,
Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project, Lancet Lond Engl. 13 janv, vol.357, issue.9250, pp.89-95, 2001. ,
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women, N Engl J Med. 31 mars, vol.352, issue.13, pp.1293-304, 2005. ,
Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin, Am J Cardiol. 15 sept, vol.98, issue.6, pp.746-50, 2006. ,
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials, JAMA. 18 janv, vol.295, issue.3, pp.306-319, 2006. ,
Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force, Ann Intern Med. 17 mars, vol.150, issue.6, pp.405-415, 2009. ,
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Antithrombotic Trialists' (ATT) Collaboration, vol.373, pp.1849-60, 2009. ,
European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), Eur Heart J. 1 août, vol.37, issue.29, pp.2315-81, 2016. ,
, Bon usage des agents antiplaquettaires, HAS
United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56), Clin Sci Lond Engl 1979. déc, vol.101, issue.6, pp.671-680, 2001. ,
, La démographie médicale en région Picardie. Situation en, Ordre National des Médecins Atlas 2015 de la région PICARDIE, 2015.
Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE), Drugs Aging, vol.20, issue.12, pp.897-903, 2003. ,
Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins, Trials. 28 août, vol.8, p.21, 2007. ,
, A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE)